PMC10031056_01
Erythema, scaling, and lichenification of the face and neck before dupilumab treatment (a); obvious fissures, erosions, and purulent exudates in the patient's neck folds after 16 weeks on treatment (b); the neck skin infection had significantly improved after 2 weeks of supportive therapy (c).
fmed-10-1027589-g0001.jpg
PMC10031056_01_fmed-10-1027589-g0001.jpg
F1
Physical examination findings included a degree of erythema, scaling, and lichenification of the face and neck (Figure 1a), trunk, and upper and lower limbs. At the 8th follow-up, there were obvious fissures, erosions, and purulent exudates in the patient's neck folds (Figure 1b). At the 9th follow-up, the neck skin infection had significantly improved (Figure 1c).
PMC10031056_02
Erythema on the face and neck worsened on the second day after each dupilumab treatment (a); 6 weeks after dupilumab discontinuation and supportive therapy (b).
fmed-10-1027589-g0002.jpg
PMC10031056_02_fmed-10-1027589-g0002.jpg
F2
Physical examination revealed generalized erythema with exudation and a tendency for erythroderma (Figure 2a). Improvements were observed after the discontinuation of dupilumab (Figure 2b).